Maze Therapeutics CSBO Atul Dandekar Exercises Options, Sells 7,500 Shares

What Happened

• Atul Dandekar, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics (MAZE), exercised 7,500 stock options and then sold the resulting 7,500 shares on July 29, 2026.
• Exercise: 7,500 shares exercised at $10.42 per share for a total exercise cost of $78,150.
• Sales: 7,100 shares sold at a weighted average price of $27.31 (proceeds reported $193,875) and 400 shares sold at a weighted average price of $27.89 (proceeds reported $11,156), for total gross sale proceeds of $205,031.
• Net difference (gross proceeds minus exercise cost) is roughly $126,881 before taxes and fees. The sales were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: July 29, 2026; Form 4 filed July 31, 2026 (appears timely).
• Exercise details: option was fully vested (vested March 17, 2025).
• Sales executed under a Rule 10b5-1 plan adopted September 29, 2025 (footnote F1).
• Reported sale prices are weighted averages; share sale prices ranged from $26.81–$27.79 (for the 7,100-share block) and $27.81–$27.96 (for the 400-share block). The filer offers to provide a breakdown of amounts at each price on request (footnotes F2, F3).
• The Form shows an M (option exercise) and S (sale) activity consistent with a cashless exercise (exercised options and sold all resulting shares). No post-transaction total holdings were provided in the data you gave.

Context

• Exercising options and immediately selling the shares (or selling enough to cover costs/taxes) is a common way for executives to realize value from vested awards and does not necessarily indicate a view on the company’s prospects.
• Purchases are generally viewed as more informative of insider optimism; in this case the activity is primarily an exercised-and-sold transaction executed under a trading plan.